Cargando…
An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use
BACKGROUND: Management of thalassemia major requires patients to have life-long access to a treatment regimen of regular blood transfusions coupled with iron chelation therapy. The objective of this study was to investigate patients' reasons for missing iron chelation therapy with desferrioxami...
Autores principales: | Ward, Alexandra, Caro, J Jaime, Green, Traci Craig, Huybrechts, Krista, Arana, Alejandro, Wait, Suzanne, Eleftheriou, Androulla |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC111194/ https://www.ncbi.nlm.nih.gov/pubmed/12015817 http://dx.doi.org/10.1186/1472-6904-2-3 |
Ejemplares similares
-
Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review
por: Caro, J Jaime, et al.
Publicado: (2002) -
Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011) -
A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011) -
Contrast Sensitivity in Patients with Beta-Thalassemia Major and Sickle Cell Disease Under Regular Transfusions and Treatment with Desferrioxamine
por: Gorezis, Spyridon, et al.
Publicado: (2010) -
A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
por: Pepe, Alessia, et al.
Publicado: (2011)